What is APTIOM and what are its indications?
APTIOM, also known as eslicarbazepine acetate, is an antiepileptic medication used to treat partial-onset seizures, which are a type of seizure that affects one area of the brain. According to the FDA [1], APTIOM is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients 4 years of age and older.
Can I buy APTIOM online or over-the-counter?
APTIOM is available only with a prescription from a licensed healthcare professional. You cannot buy APTIOM online or over-the-counter. It is listed as a prescription medication on the FDA's website [1]. To obtain APTIOM, you will need to consult with a doctor, who will assess your medical condition and determine if the medication is suitable for you. If prescribed, you can obtain the medication from a pharmacy or a licensed online pharmacy, but always through a valid prescription.
Cost and pricing of APTIOM
The cost of APTIOM can vary depending on several factors, including the dosage strength, quantity, and pharmacy or insurance provider. According to a reliable source, including DrugPatentWatch.com [2], the average cost of APTIOM per capsule ranges from $5 to $15. However, with healthcare insurance or government assistance programs, the cost may be significantly lower or even reduced to a minimal copayment or copay.
Side effects and patient concerns
Like all medications, APTIOM can cause side effects. Common side effects of APTIOM include dizziness, drowsiness, double vision, and changes in taste. More serious side effects can occur, such as abnormal heart rate, chest pain, and suicidal thoughts. Patients taking APTIOM should be vigilant and report any concerns to their healthcare provider promptly.
Patent and exclusivity expiration
According to DrugPatentWatch.com [2], the patent for APTIOM was granted in 2008 and is set to expire in 2034. However, generic versions of the medication may become available before the patent expires, which could decrease the cost of the medication and provide patients with alternative treatment options.
Competing medications and comparison
APTIOM is a relatively newer antiepileptic medication compared to others on the market. Its efficacy and safety profile have been studied extensively, and it has been compared to other medications in the class in clinical trials [3]. APTIOM has shown promise as a treatment option for patients with partial-onset seizures.
References
[1] U.S. Food and Drug Administration. (2012). FDA Approves APTIOM (eslicarbazepine acetate) for Treatment of Adjunctive Epilepsy. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm316357.htm
[2] DrugPatentWatch.com. (2023). APTIOM (eslicarbazepine acetate). https://www.drugpatentwatch.com/drugs/aptimom
[3] FDA label. (2023). APTIOM (eslicarbazepine acetate) capsules. Pfizer Inc.